Akari Therapeutics Plc (AKTX) Stock Price & Analysis
Akari Therapeutics Plc (AKTX) fell 2.88% to USD 15 as of June 10, 2026 at 05:07 UTC, according to Nexqual real-time market data.
AKTX last closed at USD 15.45; the session ranged USD 14.48–15.91 on volume of 16,348 shares. Market capitalization is $23.62M, with a 52-week range of USD 3.02–51.96 (NCM). Source: Nexqual, June 10, 2026 at 05:07 UTC.
Key Statistics (as of June 10, 2026 at 05:07 UTC)
| Price | USD 15 |
|---|---|
| Change | ▼ 2.88% (down) |
| Previous Close | USD 15.45 |
| Open | USD 15.91 |
| Day Range | USD 14.48 – 15.91 |
| 52-Week Range | USD 3.02 – 51.96 |
| Volume | 16,348 shares |
| Market Cap | $23.62M |
| Exchange | NCM |
Technical Analysis (AKTX)
Nexqual's technical model rates AKTX "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:07 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.18 (neutral) |
| vs SMA50 | Above (USD 7.38) |
| MACD | 2.73 (positive) |
Analyst Ratings (AKTX)
Wall Street analysts rate AKTX "None" based on 1 analysts, with a mean price target of USD 26.78 (range USD 26.78–26.78), per Nexqual as of June 10, 2026 at 05:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 26.78 |
| High Target | USD 26.78 |
| Low Target | USD 26.78 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (AKTX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0 vs est -2.8 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -4.4 ▲ beat |
| 2025-06-30 | USD -3.92 vs est -4.8 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:07 UTC.
Financials & Fundamentals (AKTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -155.28% |
| Debt / Equity | 5.09 |
| Current Ratio | 0.27 |
| Total Cash | $2.77M |
| Total Debt | $732,000 |
| Free Cash Flow | $-12.47M |
Source: Nexqual, June 10, 2026 at 05:07 UTC.
Financial Health Score (AKTX)
Nexqual rates Akari Therapeutics Plc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$11M |
| Efficiency | Critical — ROE -155%, ROA -18.0% |
Ownership (AKTX)
| Insider Ownership | +34.94% |
|---|---|
| Institutional Ownership | +8.42% |
| Shares Outstanding | 1.57M |
| Float | 516,610 |
| Short % of Float | +38.71% |
Source: Nexqual, June 10, 2026 at 05:07 UTC.
Leadership (AKTX)
Akari Therapeutics Plc is led by Abizer Gaslightwala (age 51), CEO, President & Director, per Nexqual as of June 10, 2026 at 05:07 UTC.
| CEO, President & Director | Abizer Gaslightwala (age 51) |
|---|---|
| Interim Chief Financial Officer | Kameel D. Farag (age 46) |
| Executive Director & Head of Oncology | Satyajit Mitra (age 50) |
Major Backers & Investors (AKTX)
Notable institutional backers of Akari Therapeutics Plc include Armistice Capital, LLC, Cresset Asset Management, LLC, according to Nexqual as of June 10, 2026 at 05:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 3.4% |
| Cresset Asset Management, LLC | 1.8% |
Source: Nexqual, June 10, 2026 at 05:07 UTC.
From Akari Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- However, our strategy is new and unproven, and we cannot guarantee that we will be successful in our efforts.   Our differentiated ADC discovery and development platform (our "ADC Platform") enables us to generate a range of ADC product candidates that pair our novel payloads with biologically validated antibody targets prevalent in cancer tumors.
- Drug Development Process   In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act ("FDCA") and in the case of biologics, also under the Public Health Service Act ("PHSA") and the implementing regulations for both statutes.
- In addition, for products under accelerated approval, FDA generally requires all promotional materials, including launch materials, to be submitted for prior review.   Post-Approval Requirements   Once approval of an NDA or BLA is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems are identified after the product reaches the market.
- A lower P-value, indicates stronger evidence to reject the null hypothesis.         The use of our proprietary L22 linker in AKTX-101 may contribute to a safety profile that has the potential to be superior to currently approved Trop-2-targeting ADCs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACHV | Achieve Life Sciences, Inc. | USD 5.6 | ▲ 9.16% |
| BPTH | Bio-Path Holdings, Inc. | USD 0.04 | ▼ 10% |
| CBIO | Crescent Biopharma, Inc. | USD 18 | ▲ 0% |
| BNTC | Benitec Biopharma Inc. | USD 10.81 | ▲ 2.46% |
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:07 UTC. This page is informational and not investment advice.